Mechanistic biomarkers for clinical decision making in rheumatic diseases

Nature Reviews Rheumatology

Volumn 9, Issue 5, 2013, Pages 267-276

  Robinson, William H ^a   Lindstrom, Tamsin M ^b   Cheung, Regina K ^b   Sokolove, Jeremy ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BETA INTERFERON; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CXCL13 CHEMOKINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA ANTIBODY; IMATINIB; INFLIXIMAB; INTERFERON ANTIBODY; INTERLEUKIN 1; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB;

ANTIBODY DETECTION; ASYMPTOMATIC DISEASE; BONE RADIOGRAPHY; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DAS28; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DRUG RESEARCH; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MEDICAL ASSESSMENT; MEDICAL RESEARCH; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOLOGICAL MARKERS; DECISION MAKING; HUMANS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 84877624922     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.14     Document Type: Review

References (103)

1. Atkinson, A. J.et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (20016p
2. Logothetis, N. K. What we can do and what we cannot do with fMRI. Nature 453, 869-878 (20086p
3. Fu, Q. Schoenhoff, F. S., Savage, W. J., Zhang, P. Van Eyk, J. E. Multiplex assays for biomarker research and clinical application: Translational science coming of age. Proteomics Clin. Appl. 4, 271-284 (20106p
4. Cho, J. H. & Gregersen, P. K. Genomics and the multifactorial nature of human autoimmune disease. N. Engl. J. Med. 365, 1612-1623 (20116p
5. Walsh, G. M. Canakinumab for the treatment of cryopyrin-associated periodic syndromes. Drugs Today (Barc.) 45, 731-735 (20096p
6. Karlson, E. W.et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann. Rheum. Dis. 69, 54-60 (20106p
7. Arbuckle, M. R.et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526-1533 (20036p
8. Berger, T.et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 349, 139-145 (20036p
9. Soeldner, J. S., Tuttleman, M., Srikanta, S., Ganda, O. P. & Eisenbarth, G. S. Insulin-dependent diabetes mellitus and autoimmunity: Islet-cell autoantibodies, insulin autoantibodies, and beta-cell failure. N. Engl. J. Med. 313, 893-894 (19856p
10. Sokolove J.et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 7, e35296 (20126p
11. Klarenbeek, N. B.et al. The impact of four dynamic, goal-steered treatment strategies on the 5year outcomes of rheumatoid arthritis patients in the BeSt study. Ann. Rheum. Dis. 70, 1039-1046 (20116p
12. Guermazi, A.et al. Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: The MOST study. Ann. Rheum. Dis. 70, 805-811 (20116p
13. Hunter, D. J.et al. The reliability of a new scoring system for knee osteoarthritis MRI and the validity of bone marrow lesion assessment: BLOKS (Boston Leeds Osteoarthritis Knee Score). Ann. Rheum. Dis. 67, 206-211 (20086p
14. Peterfy, C. G.et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 12, 177-190 (20046p
15. Blanco, F. J. & Ruiz-Romero, C. Osteoarthritis: metabolomic characterization of metabolic phenotypes in OA. Nat. Rev. Rheumatol. 8, 130-132 (20126p
16. Hoch, J. M. Mattacola, C. G.,Medina McKeon, J. M., Howard, J. S. & Lattermann, C. Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: A systematic review and meta-analysis. Osteoarthritis Cartilage 19, 1396-1404 (20116p
17. Attur, M., Krasnokutsky-Samuels, S., Samuels, J. & Abramson, S. B. Prognostic biomarkers in osteoarthritis. Curr. Opin. Rheumatol. 25, 136-144 (20136p
18. van Leeuwen, M. A.et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: A prospective study during the first three years of the disease. Br. J. Rheumatol. 32 (Suppl. 3), 9-13 (19936p
19. Eastman, P. S.et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J. Pharm. Biomed. Anal. 70, 415-424 (20126p
20. Ludwig, J. A. & Weinstein, J. N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5, 845-856 (20056p
21. Epperly, T. D., Moore, K. E. & Harrover, J. D. Polymyalgia rheumatica and temporal arthritis. Am. Fam. Physician 62, 789-796 (20006p
22. Kasitanon, N., Petri, M., Haas, M., Magder, L. S. & Fine, D. M. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: A retrospective study of 29 cases. Lupus 17, 40-45 (20086p
23. Syversen, S. W.et al. Biomarkers in early rheumatoid arthritis: Longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann. Rheum. Dis. 69, 845-850 (20106p
24. Hama, M.et al. Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab - preliminary data. Rheumatol. Int. 32, 1327-1333 (20126p
25. US Department of Health and Human Services. Draft guidance for industry on qualification process for drug development tools [online], http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM230597.pdf (20106p
26. Woodcock, J. & Woosley, R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 59, 1-12 (20086p
27. Chang, D. M.,Weinblatt, M. E. & Schur, P. H. The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J. Rheumatol. 19, 1678-1682 (19926p
28. Elliott, M. J.et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110 (19946p
29. Haringman, J. J.et al. Synovial tissue macrophages: A sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64, 834-838 (20056p
30. Yao, Y.et al. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an antiinterferonα monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60, 1785-1796 (20096p
31. Farina, G., Lafyatis, D., Lemaire, R. & Lafyatis, R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 62, 580-588 (20106p
32. Arrowsmith, J. Trial watch: phase II failures: 2008-2010 Nat. Rev. Drug Discov. 10, 328-329 (20116p
33. Arrowsmith, J. Trial watch: phase III and submission failures: 2007-2010 Nat. Rev. Drug Discov. 10, 87 (20116p
34. Trusheim, M. R., Berndt, E. R. & Douglas, F. L. Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6, 287-293 (20076p
35. Higgins, M. J. & Baselga, J. Targeted therapies for breast cancer. J. Clin. Invest. 121, 3797-3803 (20116p
36. Ernst, T., La Rosée, P., Müller, M. C. & Hochhaus, A. BCR-ABL mutations in chronic myeloid leukemia. Hematol. Oncol. Clin. North Am. 25, 997-1008, v-vi (20116p
37. Sachdev, J. C. & Jahanzeb, M. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin. Breast Cancer 12, 19-29 (20126p
38. Pao, W.et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (20056p
39. Owczarczyk, K.et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci. Transl. Med. 21, 101ra92 (20116p
40. Cohen, S. B.et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793-2806 (20066p
41. Emery, P.et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390-1400 (20066p
42. Dickson, M. & Gagnon, J. P. Key factors in the rising cost of new drug discovery and development. Nat. Rev. Drug Discov. 3, 417-429 (20046p
43. Fransen, J. van Riel, P. L. The Disease Activity Score and the EULAR response criteria. Clin. Exp. Rheumatol. 23, S93-S99 (20056p
44. Park, J. W.et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin. Cancer Res. 10, 3885-3896 (20046p
45. Liu, E. T. Mechanism-derived gene expression signatures and predictive biomarkers in clinical oncology. Proc. Natl Acad. Sci. USA 102, 3531-3532 (20056p
46. Chang, H. Y.et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738-3743 (20056p
47. Chung, L.et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum. 60, 584-591 (20096p
48. Axtell, R. C.et al. T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16, 406-412 (20106p
49. Lee, L. F.et al. IL7 promotes T(H)1 development and serum IL7 predicts clinical response to interferon-β in multiple sclerosis. Sci. Transl. Med. 3, 93ra68 (20116p
50. Agostini, L.et al. NALP3 forms an IL1βprocessing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319-325 (20046p
51. Gattorno, M.et al. The pattern of response to antiinterleukin1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58, 1505-1515 (20086p
52. Allantaz, F.et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL1 blockade. J. Exp. Med. 204, 2131-2144 (20076p
53. Niewold, T. B. Interferon alpha as a primary pathogenic factor in human lupus. J. Interferon Cytokine Res. 31, 887-892 (20116p
54. Hooks, J. J.et al. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301, 5-8 (19796p
55. Banchereau, J. Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25, 383-392 (20066p
56. Hua, J., Kirou, K., Lee, C. & Crow, M. K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 54, 1906-1916 (20066p
57. Takemura, S.et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 167, 1072-1080 (20016p
58. Lisignoli, G.et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: Activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and βNacetylhexosaminidase release. J. Cell. Physiol. 194, 71-79 (20036p
59. Meeuwisse, C. M.et al. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum. 63, 1265-1273 (20116p
60. Rosengren, S., Wei, N., Kalunian, K. C., Kavanaugh, A. & Boyle, D. L. CXCL13: A novel biomarker of Bcell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 50, 603-610 (20116p
61. Bugatti S.et al. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs Arthritis Res. Ther. 14, R34 (20126p
62. Rioja, I.et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 58, 2257-2267 (20086p
63. Boulé, M. W.et al. Toll-like receptor 9dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199, 1631-1640 (20046p
64. Kelly, K. M.et al. "Endogenous adjuvant" activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum. 54, 1557-1567 (20066p
65. Lövgren, T.et al. Induction of interferon-α by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum. 54, 1917-1927 (20066p
66. Marshak-Rothstein, A. & Rifkin, I. R. Immunologically active autoantigens: The role of Toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol. 25, 419-441 (20076p
67. Means, T. K.et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115, 407-417 (20056p
68. Savarese, E.et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107, 3229-3234 (20066p
69. Niewold, T. B., Hua, J., Lehman, T. J., Harley, J. B. & Crow, M. K. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 8, 492-502 (20076p
70. Sokolove, J., Zhao, X., Chandra, P. E. & Robinson, W. H. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor. Arthritis Rheum. 63, 53-62 (20116p
71. van de Sande, M. G.et al. Different stages of rheumatoid arthritis: Features of the synovium in the preclinical phase. Ann. Rheum. Dis. 70, 772-777 (20116p
72. Verge C.F.et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA2 autoantibodies Diabetes 45, 926-933 (19966p
73. Ziegler, A. G., Hummel, M., Schenker, M. & Bonifacio, E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: The 2year analysis of the German BABYDIAB Study. Diabetes 48, 460-468 (19996p
74. Nielen, M. M.et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum. 50, 380-386 (20046p
75. Rantapää-Dahlqvist, S.et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48, 2741-2749 (20036p
76. Deane, K. D.et al. The number of elevated cytokines/chemokines in pre-clinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 62, 3161-3172 (20106p
77. Kokkonen, H.et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 62, 383-391 (20106p
78. Nielen, M. M.et al. Increased levels of Creactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 50, 2423-2427 (20046p
79. Robinson, W. H.et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol. 21, 1033-1039 (20036p
80. Garren, H.et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann. Neurol. 63, 611-620 (20086p
81. van Dongen, H.et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56, 1424-1432 (20076p
82. de Groot, A. S. & Scott, D. W. Immunogenicity of protein therapeutics. Trends Immunol. 28, 482-490 (20076p
83. Alevizos, I. & Illei, G. G. MicroRNAs as biomarkers in rheumatic diseases. Nat. Rev. Rheumatol. 6, 391-398 (20106p
84. Ceribelli, A.et al. MicroRNAs in systemic rheumatic diseases. Arthritis Res. Ther. 13, 229 (20116p
85. Curtale, G.et al. An emerging player in the adaptive immune response: microRNA146a is a modulator of IL2 expression and activation-induced cell death in T lymphocytes. Blood 115, 265-273 (20106p
86. Pope, R. M. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev. Immunol. 2, 527-535 (20026p
87. Nakasa, T.et al. Expression of microRNA146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 58, 1284-1292 (20086p
88. Niimoto, T.et al. MicroRNA146a expresses in interleukin17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet. Disord. 11, 209 (20106p).
89. Pauley, K. M.et al. Upregulated miR146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res. Ther. 10, R101 (20086p
90. Pauley, K. M.et al. Altered miR146a expression in Sjögren's syndrome and its functional role in innate immunity. Eur. J. Immunol. 41, 2029-2039 (20116p
91. Tang, Y.et al. MicroRNA146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 60, 1065-1075 (20096p
92. O'Connell, R. M.et al. MicroRNA155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33, 607-619 (20106p
93. Blüml, S.et al. Essential role of microRNA155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 63, 1281-1288 (20116p
94. McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205-2219 (20116p
95. Gabay, C., Lamacchia, C. & Palmer, G. IL1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6, 232-241 (20106p
96. Tak, P. P.et al. The effects of interferon beta treatment on arthritis. Rheumatology (Oxford) 38, 362-369 (19996p
97. Triantaphyllopoulos, K. A., Williams, R. O., Tailor, H. & Chernajovsky, Y. Amelioration of collagen-induced arthritis and suppression of interferon-γ, interleukin12, and tumor necrosis factor α production by interferon-β gene therapy. Arthritis Rheum. 42, 90-99 (19996p
98. van Holten, J.et al. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64, 64-69 (20056p
99. Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110-2121 (20116p
100. van den Broek, M., Huizinga, T. W., Dijkmans, B. A. & Allaart, C. F. Drug-free remission: Is it already possible? Curr. Opin. Rheumatol. 23, 266-272 (20116p
101. Walsh, R. J.et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 56, 3784-3792 (20076p
102. Båve, U.et al. Activation of the type I interferon system in primary Sjögren's syndrome: A possible etiopathogenic mechanism. Arthritis Rheum. 52, 1185-1195 (20056p
103. York, M. R.et al. A macrophage marker, Siglec1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum. 56, 1010-1020 (20076p